Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CCS1477 + Enzalutamide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CCS1477 | CCS-1477|CCS 1477 | CBP/p300 inhibitor 11 | CCS1477 binds to and inhibits p300 (EP300) and CBP (CREBBP), potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (J Clin Oncol 35, 2017 (suppl; abstr 11590)). | |
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 43 | Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03568656 | Phase Ib/II | CCS1477 Abiraterone + CCS1477 CCS1477 + Enzalutamide | Study to Evaluate CCS1477 in Advanced Tumours | Recruiting | USA | GBR | FRA | ESP | 2 |